As of December 31, 2022, Impel had approximately $60.7 million in cash and cash equivalents. The Company believes, based on its current operating plan, that it has sufficient capital to fund operations into the third quarter of 2023.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IMPL:
- Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023
- Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March
- Impel Pharmaceuticals announces strategic reprioritization, departure of CMO
- Impel Pharmaceuticals Announces Strategic Repriortization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity